Integra LifeSciences Holdings Co. (NASDAQ:IART) Shares Purchased by LSV Asset Management

LSV Asset Management increased its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 14.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 237,900 shares of the life sciences company's stock after purchasing an additional 29,300 shares during the period. LSV Asset Management owned 0.31% of Integra LifeSciences worth $5,396,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in IART. Quadrant Capital Group LLC raised its holdings in shares of Integra LifeSciences by 5,960.9% during the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock valued at $32,000 after buying an additional 1,371 shares during the period. Nisa Investment Advisors LLC raised its stake in shares of Integra LifeSciences by 599.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock valued at $74,000 after purchasing an additional 2,800 shares during the period. Empowered Funds LLC purchased a new position in shares of Integra LifeSciences in the fourth quarter valued at $180,000. Mitsubishi UFJ Asset Management UK Ltd. acquired a new stake in Integra LifeSciences during the 4th quarter valued at $204,000. Finally, Romano Brothers AND Company purchased a new stake in Integra LifeSciences during the 4th quarter worth $204,000. 84.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on IART shares. Argus upgraded Integra LifeSciences from a "hold" rating to a "buy" rating in a research note on Monday, March 31st. Truist Financial lowered their price objective on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating for the company in a research note on Friday, April 11th. Three research analysts have rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Integra LifeSciences has a consensus rating of "Hold" and a consensus target price of $22.71.

Integra LifeSciences Stock Performance

Shares of IART traded up $0.08 during mid-day trading on Friday, reaching $15.83. 429,645 shares of the company's stock traded hands, compared to its average volume of 1,052,115. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20. The business's 50-day moving average price is $21.30 and its 200-day moving average price is $22.22. The stock has a market capitalization of $1.22 billion, a P/E ratio of -175.87, a price-to-earnings-growth ratio of 0.73 and a beta of 1.24. Integra LifeSciences Holdings Co. has a 12 month low of $15.46 and a 12 month high of $32.66.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, beating analysts' consensus estimates of $0.85 by $0.12. The company had revenue of $442.65 million for the quarter, compared to analyst estimates of $445.15 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company's quarterly revenue was up 11.5% compared to the same quarter last year. During the same period last year, the company earned $0.89 earnings per share. Equities analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.